Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab + Tiragolumab +/- Atezolizumab in R/R B-NHL
NCT05315713Phase 2Terminated
- Sponsor
- Roche
- Start
- May 2022
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors, Bispecific Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of mosunetuzumab, tiragolumab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Roche. Started May 2022; status: terminated.
02
Drugs
mosunetuzumabtiragolumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05315713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315713.